论文部分内容阅读
曲妥珠单抗(trastuzumab,商品名herceptin)针对人表皮生长因子受体2(Her-2)过表达的乳腺癌患者疗效肯定。然而,一部分患者对曲妥珠单抗产生原发性或获得性耐药。本文对耐药机制及耐药后的治疗策略进行综述。
The efficacy of trastuzumab (herceptin) against breast cancer patients overexpressing human epidermal growth factor receptor 2 (Her-2) was confirmed. However, some patients develop primary or acquired resistance to trastuzumab. This article reviews the mechanism of drug resistance and treatment strategy after drug resistance.